Edition:
United States

Egalet Corp (EGLT.OQ)

EGLT.OQ on NASDAQ Stock Exchange Global Market

1.04USD
8 Dec 2017
Change (% chg)

$0.04 (+4.00%)
Prev Close
$1.00
Open
$1.00
Day's High
$1.05
Day's Low
$1.00
Volume
148,306
Avg. Vol
155,467
52-wk High
$10.00
52-wk Low
$0.80

Latest Key Developments (Source: Significant Developments)

Egalet Corp's Phase 3 Study Of Egalet-002 In Patients With Moderate-To-Severe Chronic Low Back Pain Meets Primary Endpoint​
Tuesday, 28 Nov 2017 06:02am EST 

Nov 28 (Reuters) - Egalet Corp ::EGALET ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY EVALUATING EFFICACY AND SAFETY OF EGALET-002 IN PATIENTS WITH MODERATE-TO-SEVERE CHRONIC LOW BACK PAIN.EGALET CORP - ‍EGALET-002 WAS GENERALLY WELL-TOLERATED AND NO NEW SAFETY CONCERNS WERE IDENTIFIED IN STUDY​.EGALET CORP - ‍STUDY OF EGALET-002 MET ITS PRIMARY ENDPOINT​.  Full Article

Egalet Corp Says ‍Apotex Has Lost Right To Launch An Authorized Generic Version Of Sprix Nasal Spray​
Monday, 27 Nov 2017 05:35pm EST 

Nov 27 (Reuters) - Egalet Corp ::EGALET CORP - ‍COMPANY DID NOT RECEIVE ANY WRITTEN NOTIFICATION ON OR BEFORE NOTIFICATION DEADLINE FOR PRODUCT LAUNCH FROM APOTEX CORP & APOTEX INC​.EGALET CORP - ‍APOTEX HAS LOST RIGHT TO LAUNCH AN AUTHORIZED GENERIC VERSION OF SPRIX NASAL SPRAY​.EGALET CORP - ‍IF APOTEX IS ABLE TO SATISFY REQUIREMENTS FOR LAUNCHING AN UNAUTHORIZED GENERIC, IT WOULD BE PERMITTED TO DO SO IN SEPTEMBER 2018​.  Full Article

Egalet Q2 loss per share $1.04
Wednesday, 9 Aug 2017 04:02pm EDT 

Aug 9 (Reuters) - Egalet Corp :Egalet announces second quarter 2017 financial results and expense reduction plan.Q2 loss per share $1.04.Says ‍announcing an expense reduction plan that includes a corporate restructuring​.Qtrly net revenue grew to $6.3 million representing increases of 81 percent over q2 of 2016 and 15 percent over Q1 of 2017.Egalet corp says company restructuring expected to reduce costs by 35%.Egalet - reducing workforce, excluding sales team, by nearly 40 percent. With this initiative, along with elimination of certain other expenditures​.Says ‍with the initiative expects total costs and expenses to be between $55 and $60 million in 2018​.Egalet Corp - anticipates that its existing cash, cash equivalents and marketable securities, will enable Egalet to fund its operations into 2020​.Says ‍total net product sales were $6.3 million for quarter ended June 30, 2017 compared to $3.5 million​.  Full Article

Highbridge Capital Management LLC reports 9.58 pct passive stake in Egalet Corp as of July 6 - SEC filing
Monday, 17 Jul 2017 04:58pm EDT 

July 17 (Reuters) - Egalet Corp :Highbridge Capital Management LLC reports a 9.58 percent passive stake in Egalet Corp as of July 6, 2017 - SEC filing.  Full Article

Egalet announces pricing of public offering of common stock and warrants
Thursday, 6 Jul 2017 09:24am EDT 

July 6 (Reuters) - Egalet Corp ::Egalet announces pricing of public offering of common stock and warrants.Says public offering of 16.7 million common shares priced at $1.80per share.  Full Article

Egalet announces proposed public offering of common stock, warrants
Wednesday, 5 Jul 2017 04:01pm EDT 

July 5 (Reuters) - Egalet Corp ::Egalet announces proposed public offering of common stock and warrants.Egalet Corp - intends to offer and sell shares of its common stock and warrants to purchase shares of common stock in an underwritten public offering.Egalet Corp says anticipates using net proceeds from offering, to support its commercial sales and marketing efforts with respect to ARYMO.  Full Article

Egalet receives complete response letter from US FDA for prior approval supplement for 10 mg and 15 mg dosage strengths of oxaydo
Tuesday, 20 Jun 2017 09:06am EDT 

June 20 (Reuters) - Egalet Corp :Egalet receives complete response letter from U.S. Food and Drug Administration for prior approval supplement for 10 mg and 15 mg dosage strengths of Oxaydo.Egalet - FDA has requested more information regarding effect of food on oxaydo 15 mg and intranasal abuse-deterrent properties of oxaydo 10 mg and 15 mg.Says there is no evidence that oxaydo has reduced abuse liability compared to immediate-release oxycodone.  Full Article

Egalet partners with Ascend Therapeutics to co-promote Sprix nasal spray
Wednesday, 7 Jun 2017 06:02am EDT 

June 7 (Reuters) - Egalet Corp -:Egalet partners with Ascend Therapeutics® U.S., LLC to co-promote sprix® nasal spray.Says promotional activities will begin in Q3 and term of co-promote relationship is two years.Payments associated with partnership with ascend therapeutics will not be disclosed.  Full Article

Egalet Q1 loss per share $1.02
Wednesday, 10 May 2017 06:02am EDT 

May 10 (Reuters) - Egalet Corp :Egalet reports first quarter 2017 financial results.Q1 loss per share $1.02.Q1 revenue $5.4 million versus $2.7 million.Q1 revenue view $6.9 million -- Thomson Reuters I/B/E/S.Q1 earnings per share view $-0.86 -- Thomson Reuters I/B/E/S.Egalet corp - as of march 31, 2017, egalet had cash and marketable securities totaling $105.3 million.  Full Article

Egalet announces U.S. FDA acceptance of file for prior approval supplement for Oxaydo
Tuesday, 18 Apr 2017 06:23am EDT 

April 18 (Reuters) - Egalet Corp :Egalet announces U.S. Food and Drug Administration acceptance of file for prior approval supplement for Oxaydo(oxycodone HCL, USP) tablets C-II 10 mg and 15 mg dosage strengths.Egalet Corp - FDA goal date is June 17, 2017.Egalet Corp - there is no evidence that Oxaydo has reduced abuse liability compared to immediate-release oxycodone.  Full Article

BRIEF-Egalet Says Notified Verbally By CVS Caremark That Sprix Will No Longer Be On Formulary For A Portion Of Commercial Covered Lives Beginning 2018

* EGALET - NOTIFIED VERBALLY BY CVS CAREMARK THAT SPRIX WILL NO LONGER BE ON FORMULARY FOR A PORTION OF COMMERCIAL COVERED LIVES BEGINNING JAN 1, 2018